 |
Anacor Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 15, 2012
|
6.8 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals announced today that David Perry, the company's
Chief Executive Officer, will provide a company overview at the
following upcoming investor conferences:
Citi Global Health Care Conference on Monday February 27, 2012 at
11:30 a.m. ET in New York, New York.
RBC Global Healthcare Conference on Tuesday February 28, 2012 at 8:00
...
|
|
Anacor Pharmaceuticals Announces the Sale of 3.25 Million Shares of Common Stock
Feb 8, 2012
|
7.1 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (Nasdaq:ANAC), today announced the sale of 3.25
million shares of its common stock for gross proceeds of $21,450,000
pursuant to an underwriting agreement with Canaccord Genuity acting as
the sole bookrunner. In addition, the Company has granted the
underwriters a 30-day option to purchase up to an additional 487,500
shares of common stock to cover over-allotments, if any.
...
|
|
Anacor Pharmaceuticals Announces Positive Preliminary Results from Two Safety Studies of AN2728 and Updates Atopic Dermatitis Results and Regulatory Status
Feb 7, 2012
|
57.0 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today positive
preliminary results from two safety studies of AN2728 - a maximal use
systemic exposure (MUSE) study in psoriatic patients and a local
tolerability study. The results of these two studies demonstrate that
AN2728 Ointment, 2% appears to be safe and well-tolerated when applied
to very large body surface areas and that it is well-tolerated when
...
|
|
Anacor Pharmaceuticals Announces That Its Partner GSK Has Voluntarily Paused Enrollment of Ongoing GSK ‘052 Phase 1 and 2 Clinical Trials
Feb 6, 2012
|
7.6 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its partner
GlaxoSmithKline (GSK) has voluntarily paused enrollment in its current
clinical trials of GSK2251052 (GSK ‘052) due to a recently identified
microbiological finding in a small number of patients in the Phase 2b
trial of GSK ‘052 for the treatment of complicated urinary tract
infections (cUTI). GSK is in the process of obtaini...
|
|
Anacor Pharmaceuticals Completes Enrollment in Second of Two Phase 3 Trials of Tavaborole for Onychomycosis
Dec 22, 2011
|
6.9 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has
completed the enrollment of approximately 600 patients in the second of
its two Phase 3 trials of tavaborole (formerly known as AN2690), a
topical anti-fungal product candidate for the treatment of
onychomycosis, a fungal infection of the nail and nail bed that affects
approximately 35 million people in the United States.
...
|
|
Anacor Pharmaceuticals Announces Positive Preliminary Results from Phase 2a Trial of AN2728 and AN2898 in Atopic Dermatitis
Dec 12, 2011
|
57.9 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced positive preliminary
results from a Phase 2a trial of its two boron-based phosphodiesterase-4
(PDE-4) inhibitors, AN2728 and AN2898, in mild-to-moderate atopic
dermatitis, a chronic rash characterized by inflammation and itching.
The primary endpoint for both compounds was successfully achieved after
28 days of twice-daily treatment, with 64% of AN2728-treated...
|
|
Anacor Pharmaceuticals Reports Third Quarter 2011 Financial Results
Nov 10, 2011
|
21.4 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) reported today its accomplishments
and financial results for the third quarter ended September 30, 2011.
"In the third quarter, we focused on completing the enrollment of our
two Phase 3 trials of tavaborole, formerly known as AN2690, our topical
antifungal product for onychomycosis, preparing for our End of Phase 2
discussions with the FDA for AN2728 in...
|
|
Anacor Pharmaceuticals Completes Enrollment in First of Two Phase 3 Trials of AN2690 for Onychomycosis
Nov 9, 2011
|
8.4 KB |
| |
Tavaborole granted as generic name for AN2690
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has
completed enrollment in the first of two Phase 3 trials of tavaborole
(formerly known as AN2690), a topical anti-fungal product candidate for
the treatment of onychomycosis. Onychomycosis is a fungal infection of
the nail and nail bed that affects approximately 35 million peo...
|
|
Anacor Pharmaceuticals Announces Third Quarter 2011 Financial Results Conference Call and Webcast
Nov 3, 2011
|
6.8 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results
for the third quarter ended September 30, 2011, on Thursday November 10,
2011 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will
be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during
which management will discuss the company's financial results and recent
developments. The call can be accessed by diali...
|
|
Anacor Pharmaceuticals to Present at the 10th Annual Bio Investor Forum
Oct 21, 2011
|
6.4 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (Nasdaq:ANAC) announced today that David Perry,
the company's Chief Executive Officer, will provide a company overview
at the 10th Annual Bio Investor Forum at 10:30 a.m. PT on
Wednesday October 26, 2011 in San Francisco, California. The
presentation will be webcast live and may be accessed under "Events and
Presentations" on the Investors page of Anacor's website at www.anacor.com.
...
|
|
NIH Awards Funding to UCSF for the Discovery of Antimalarial Agents in Collaboration with Anacor Pharmaceuticals
Oct 11, 2011
|
7.5 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that the University
of California San Francisco (UCSF) has been awarded $718,136 in funding
from the National Institutes of Health (NIH) to discover and optimize
novel oxaboroles as antimalarial drugs in collaboration with Anacor
Pharmaceuticals. The NIH grant provides support for the period beginning
September 30, 2011 and ending September 29, 2012.
...
|
|
Anacor's Partner GlaxoSmithKline Awarded up to $94 Million in U.S. Government Funding to Support Development of GSK ‘052, a Novel Gram-negative Antibiotic Discovered by Anacor
Sep 7, 2011
|
10.3 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its partner,
GlaxoSmithKline (GSK), has been awarded a contract with the U.S.
Department of Health and Human Services' (HHS) Biomedical Advanced
Research and Development Authority (BARDA) to support the ongoing
development of GSK2251052 (GSK ‘052, formerly AN3665), a novel
boron-based Gram-negative systemic antibiotic discovered by Anacor.
...
|
|
Anacor and GlaxoSmithKline Amend and Expand R&D Collaboration
Sep 6, 2011
|
8.9 KB |
| |
Anacor to receive $5 million upfront payment and up to an
additional $11.3 million in proceeds by year end 2012
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has amended
and expanded its research and development collaboration with
GlaxoSmithKline (GSK) to provide GSK the option to extend its rights
around the bacterial enzyme target leucyl-tRNA synthetase (LeuRS), as
...
|
|
Anacor Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference
Sep 1, 2011
|
6.3 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry,
the company's Chief Executive Officer, will provide a company overview
at the Stifel Nicolaus 2011 Healthcare Conference at 3:50 p.m. ET on
Thursday, September 8, 2011 in Boston, Massachusetts. The presentation
will be webcast live and may be accessed under "Events and
Presentations" on the Investors page of Anacor's website at www.anac...
|
|
Anacor Pharmaceuticals and Medicines for Malaria Venture Extend Development Agreement for AN3661 for the Treatment of Malaria
Aug 31, 2011
|
11.1 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that Medicines for
Malaria Venture (MMV) has extended the existing development agreement
between the two organizations to fund the clinical development of
AN3661, a boron-based drug candidate for the treatment of malaria.
On April 26, 2010, Anacor and MMV entered into a research collaboration
to apply Anacor's boron chemistry to identify ...
|
|
Anacor Pharmaceuticals Reports Second Quarter 2011 Financial Results
Aug 11, 2011
|
23.2 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) reported today its second quarter
accomplishments and financial results for the three months ended June
30, 2011.
"We continued to make progress on our lead programs in the second
quarter. We are enrolling patients in our two Phase 3 trials of AN2690
for onychomycosis, we completed our final Phase 2b trial of AN2728 for
psoriasis and are prepari...
|
|
Anacor Announces First Development Candidate in Animal Health under Research Collaboration with Eli Lilly and Company
Aug 10, 2011
|
6.7 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has
achieved the first development candidate in its animal health
collaboration with Eli Lilly and Company (Lilly). Anacor's research
collaboration with Lilly explores the use of Anacor's boron chemistry to
discover products for a variety of animal health applications. Under the
terms of the collaboration, Anacor will receive a $1 million payment...
|
|
Anacor Pharmaceuticals to Present at the 2011 Wedbush Life Sciences Conference
Aug 9, 2011
|
6.3 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (Nasdaq:ANAC) announced today that David Perry,
the company's Chief Executive Officer, will provide a company overview
at the 2011 Wedbush Life Sciences Conference at 10:35 a.m. ET on
Tuesday, August 16, 2011 in New York, New York. The presentation will be
webcast live and may be accessed under "Events and Presentations" on the
Investors page of Anacor's website at www.anacor.com.
...
|
|
Anacor Pharmaceuticals Announces Second Quarter 2011 Financial Results Conference Call and Webcast
Aug 4, 2011
|
6.8 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results
for the second quarter ended June 30, 2011, on Thursday August 11, 2011
at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be
followed by a conference call at 4:30 p.m. ET / 1:30 p.m. PT during
which management will discuss the company's financial results and recent
developments. The call can be accessed by dialing (87...
|
|
Anacor Pharmaceuticals Partnership Advances Novel Drug Candidate to Combat Sleeping Sickness
Jun 28, 2011
|
15.7 KB |
| |
PLoS Journal article highlights initial research success of a
boron-based compound, ready to enter into clinical development,
resulting from collaboration between Anacor Pharmaceuticals, DNDi,
and SCYNEXIS
PALO ALTO, Calif. & GENEVA & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
Anacor
Pharmaceuticals (NASDAQ:ANAC), the
Drugs for Neglected Diseases initiative (DNDi), and SCYNEXIS
Inc....
|
|
|
